| Year |
Citation |
Score |
| 2020 |
McEwan B, Kuppuraju M, Padalia Z, Terrett J, Kalaitzidis D. Abstract 880: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro Immunology. 80: 880-880. DOI: 10.1158/1538-7445.Am2020-880 |
0.362 |
|
| 2020 |
Padalia Z, Dunn A, Karagiannis K, McEwan B, Kuppuraju M, Sagert J, Karnik S, Dequeant M, Terrett J, Kalaitzidis D. Abstract 879: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors Immunology. DOI: 10.1158/1538-7445.Am2020-879 |
0.336 |
|
| 2019 |
McEwan B, Padalia Z, Porras A, Sagert J, Terrett JA, Ho T, Kalaitzidis D. Abstract 1428: Allogeneic CRISPR/Cas9 gene-edited CAR-T cells targeting CD33 show potent preclinical activity against AML cells Cancer Research. 79: 1428-1428. DOI: 10.1158/1538-7445.Am2019-1428 |
0.385 |
|
| 2018 |
Dar H, Henderson D, Padalia Z, Porras A, Mu D, Kyungah M, Police S, Kalaitzidis D, Terrett J, Sagert J. Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma Blood. 132: 1921-1921. DOI: 10.1182/Blood-2018-99-116443 |
0.349 |
|
| 2018 |
Padalia Z, Porras A, Dequeant ML, Sagert J, Nguyen T, John M, Allen M, Dar H, Henderson D, Mu D, Maeng K, Huang E, Spencer S, Lorson N, Gonzales P, ... ... Kalaitzidis D, et al. Abstract 2551: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells Cancer Research. 78: 2551-2551. DOI: 10.1158/1538-7445.Am2018-2551 |
0.341 |
|
| 2017 |
Lee PY, Sykes DB, Ameri S, Kalaitzidis D, Charles JF, Nelson-Maney N, Wei K, Cunin P, Morris A, Cardona AE, Root DE, Scadden DT, Nigrovic PA. The metabolic regulator mTORC1 controls terminal myeloid differentiation. Science Immunology. 2. PMID 28763796 DOI: 10.1126/Sciimmunol.Aam6641 |
0.422 |
|
| 2017 |
Kalaitzidis D, Lee D, Efeyan A, Kfoury Y, Nayyar N, Sykes DB, Mercier FE, Papazian A, Baryawno N, Victora GD, Neuberg D, Sabatini DM, Scadden DT. Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells. The Journal of Clinical Investigation. PMID 28319048 DOI: 10.1172/Jci89452 |
0.377 |
|
| 2016 |
Lee D, Wang YH, Kalaitzidis D, Ramachandran J, Eda H, Sykes DB, Raje N, Scadden DT. Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. The Journal of Clinical Investigation. PMID 26927669 DOI: 10.1172/Jci84620 |
0.42 |
|
| 2014 |
Lee D, Sykes SM, Kalaitzidis D, Lane AA, Kfoury Y, Raaijmakers MH, Wang YH, Armstrong SA, Scadden DT. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 3: 832-40. PMID 25418727 DOI: 10.1016/j.stemcr.2014.08.011 |
0.338 |
|
| 2014 |
Kalaitzidis D, Scadden DT. Deep diving in the blood stem cell-ome. The Embo Journal. 33: 2281-2. PMID 25190519 DOI: 10.15252/Embj.201489778 |
0.372 |
|
| 2014 |
Kalaitzidis D, Scadden DT. Tic-TACs: refreshing hair growth. Cell. 157: 769-70. PMID 24813602 DOI: 10.1016/J.Cell.2014.04.014 |
0.368 |
|
| 2014 |
Ng CE, Sinha A, Krivtsov A, Dias S, Chang J, Armstrong SA, Kalaitzidis D. KRas(G12D)-evoked leukemogenesis does not require β-catenin. Leukemia. 28: 698-702. PMID 24189294 DOI: 10.1038/Leu.2013.328 |
0.339 |
|
| 2013 |
Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 121: 3692-702. PMID 23487027 DOI: 10.1182/Blood-2012-05-432989 |
0.393 |
|
| 2012 |
Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 11: 429-39. PMID 22958934 DOI: 10.1016/j.stem.2012.06.009 |
0.368 |
|
| 2011 |
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Schöll C, Tothova Z, Attar EC, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 146: 697-708. PMID 21884932 DOI: 10.1016/J.Cell.2011.07.032 |
0.441 |
|
| 2011 |
Kalaitzidis D, Armstrong SA. Cancer: The flipside of Notch. Nature. 473: 159-60. PMID 21562551 DOI: 10.1038/473159A |
0.408 |
|
| 2011 |
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, et al. Erratum: AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias (Cell (2011) 146 (697-708)) Cell. 147. DOI: 10.1016/J.Cell.2011.09.015 |
0.398 |
|
| 2009 |
Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 113: 4414-24. PMID 19179468 DOI: 10.1182/blood-2008-10-182626 |
0.309 |
|
| 2008 |
Herscovitch M, Comb W, Ennis T, Coleman K, Yong S, Armstead B, Kalaitzidis D, Chandani S, Gilmore TD. Intermolecular disulfide bond formation in the NEMO dimer requires Cys54 and Cys347. Biochemical and Biophysical Research Communications. 367: 103-8. PMID 18164680 DOI: 10.1016/J.Bbrc.2007.12.123 |
0.631 |
|
| 2008 |
Chan G, Kalaitzidis D, Usenko T, Kutok J, Yang W, Mohi G, Neel B. Expression of Leukemogenic Ptpn11 Causes a Fatal Myeloproliferative Disorder by Affecting Multiple Stages of Hematopoiesis Blood. 112: 3733-3733. DOI: 10.1182/blood.v112.11.3733.3733 |
0.316 |
|
| 2007 |
Sullivan JC, Kalaitzidis D, Gilmore TD, Finnerty JR. Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis. Development Genes and Evolution. 217: 63-72. PMID 17120026 DOI: 10.1007/S00427-006-0111-6 |
0.636 |
|
| 2005 |
Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends in Endocrinology and Metabolism: Tem. 16: 46-52. PMID 15734144 DOI: 10.1016/J.Tem.2005.01.004 |
0.607 |
|
| 2004 |
Kalaitzidis D, Ok J, Sulak L, Starczynowski DT, Gilmore TD. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells. Oncogene. 23: 7580-7. PMID 15326488 DOI: 10.1038/Sj.Onc.1207912 |
0.689 |
|
| 2004 |
Gilmore TD, Starczynowski DT, Kalaitzidis D. RELevant gene amplification in B-cell lymphomas? Blood. 103: 3243-4; author reply. PMID 15070712 DOI: 10.1182/Blood-2003-11-4019 |
0.719 |
|
| 2004 |
Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 23: 2275-86. PMID 14755244 DOI: 10.1038/Sj.Onc.1207410 |
0.733 |
|
| 2003 |
Gilmore TD, Jean-Jacques J, Richards R, Cormier C, Kim J, Kalaitzidis D. Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology. 316: 9-16. PMID 14599786 DOI: 10.1016/S0042-6822(03)00562-2 |
0.593 |
|
| 2002 |
Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Oncogene. 21: 8759-68. PMID 12483529 DOI: 10.1038/Sj.Onc.1206033 |
0.655 |
|
| 2002 |
Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Letters. 181: 1-9. PMID 12430173 DOI: 10.1016/S0304-3835(01)00795-9 |
0.717 |
|
| 2002 |
Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes, Chromosomes & Cancer. 34: 129-35. PMID 11921291 DOI: 10.1002/Gcc.10051 |
0.633 |
|
| Show low-probability matches. |